AMCP Market Insights: Navigating the rapidly changing landscape of ER+/HER2- metastatic breast cancer.

IF 2.9 4区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Journal of managed care & specialty pharmacy Pub Date : 2025-10-01 DOI:10.18553/jmcp.2025.31.10-b.s1

Bridget Flavin, Denise Wolff, Laura Bobolts, Gaurang Gandhi, Ryan Haumschild, Neil Iyengar, Michael Kobernick, Rebecca Lich, Bhavesh Shah

{"title":"AMCP Market Insights: Navigating the rapidly changing landscape of ER+/HER2- metastatic breast cancer.","authors":"Bridget Flavin, Denise Wolff, Laura Bobolts, Gaurang Gandhi, Ryan Haumschild, Neil Iyengar, Michael Kobernick, Rebecca Lich, Bhavesh Shah","doi":"10.18553/jmcp.2025.31.10-b.s1","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer is the most common cancer diagnosed in women in the United States, and its impact on both patients and their caregivers, particularly in advanced or metastatic disease, is substantial. Additionally, for the most common breast cancer subtype (estrogen receptor [ER]+/human endothelial growth factor receptor 2 [HER2]-), the treatment landscape for metastatic disease is continuously evolving, making appropriate therapy sequencing challenging. To discuss navigating the rapidly changing landscape of ER+/HER2- metastatic breast cancer (mBC), AMCP Market Insights virtually convened an expert panel of managed care stakeholders in February 2025. Key insights from the discussion on ER+/HER2- mBC included addressing the patient care journey, maintaining high-quality care, managing the impact to payers, evaluating new and emerging therapies, and looking toward the future. Suggested payer best practices in ER+/HER2- mBC also emerged from the discussion.</p>","PeriodicalId":16170,"journal":{"name":"Journal of managed care & specialty pharmacy","volume":"31 10-b Suppl","pages":"S1-S14"},"PeriodicalIF":2.9000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12467767/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of managed care & specialty pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18553/jmcp.2025.31.10-b.s1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Breast cancer is the most common cancer diagnosed in women in the United States, and its impact on both patients and their caregivers, particularly in advanced or metastatic disease, is substantial. Additionally, for the most common breast cancer subtype (estrogen receptor [ER]+/human endothelial growth factor receptor 2 [HER2]-), the treatment landscape for metastatic disease is continuously evolving, making appropriate therapy sequencing challenging. To discuss navigating the rapidly changing landscape of ER+/HER2- metastatic breast cancer (mBC), AMCP Market Insights virtually convened an expert panel of managed care stakeholders in February 2025. Key insights from the discussion on ER+/HER2- mBC included addressing the patient care journey, maintaining high-quality care, managing the impact to payers, evaluating new and emerging therapies, and looking toward the future. Suggested payer best practices in ER+/HER2- mBC also emerged from the discussion.

查看原文本刊更多论文

AMCP市场洞察：引导快速变化的ER+/HER2-转移性乳腺癌

乳腺癌是美国女性中最常见的癌症，它对患者及其护理人员的影响是巨大的，特别是在晚期或转移性疾病中。此外，对于最常见的乳腺癌亚型（雌激素受体[ER]+/人内皮生长因子受体2 [HER2]-），转移性疾病的治疗前景不断发展，使适当的治疗测序具有挑战性。为了讨论如何应对快速变化的ER+/HER2-转移性乳腺癌（mBC）， AMCP Market Insights于2025年2月召集了一个管理式医疗利益相关者专家小组。关于ER+/HER2- mBC的讨论的主要见解包括解决患者护理过程，保持高质量的护理，管理对支付者的影响，评估新的和新兴的治疗方法，以及展望未来。讨论中还提出了ER+/HER2- mBC的建议付款人最佳做法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of managed care & specialty pharmacy Health Professions-Pharmacy

CiteScore

3.50

自引率

4.80%

发文量

131

期刊介绍： JMCP welcomes research studies conducted outside of the United States that are relevant to our readership. Our audience is primarily concerned with designing policies of formulary coverage, health benefit design, and pharmaceutical programs that are based on evidence from large populations of people. Studies of pharmacist interventions conducted outside the United States that have already been extensively studied within the United States and studies of small sample sizes in non-managed care environments outside of the United States (e.g., hospitals or community pharmacies) are generally of low interest to our readership. However, studies of health outcomes and costs assessed in large populations that provide evidence for formulary coverage, health benefit design, and pharmaceutical programs are of high interest to JMCP’s readership.